These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 20819950)

  • 1. Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria?
    de Cavanagh EM; Inserra F; Ferder L
    Cardiovasc Res; 2011 Jan; 89(1):31-40. PubMed ID: 20819950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From mitochondria to disease: role of the renin-angiotensin system.
    de Cavanagh EM; Inserra F; Ferder M; Ferder L
    Am J Nephrol; 2007; 27(6):545-53. PubMed ID: 17785964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the renin-angiotensin system on cardiac energy metabolism in heart failure.
    Mori J; Zhang L; Oudit GY; Lopaschuk GD
    J Mol Cell Cardiol; 2013 Oct; 63():98-106. PubMed ID: 23886814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II blockade: how its molecular targets may signal to mitochondria and slow aging. Coincidences with calorie restriction and mTOR inhibition.
    de Cavanagh EM; Inserra F; Ferder L
    Am J Physiol Heart Circ Physiol; 2015 Jul; 309(1):H15-44. PubMed ID: 25934099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
    Leiter LA; Lewanczuk RZ
    Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in metabolic disorders: hypercholesterolaemia and diabetes].
    Strawn WB
    Drugs; 2002; 62 Spec No 1():31-41. PubMed ID: 12036387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interaction between the renin-angiotensin system and peroxisome proliferator activated receptors: a hypothesis including the participation of mitochondria in aging.
    de Cavanagh EM; Piotrkowski B; Fraga CG
    Front Biosci; 2007 Jan; 12():1049-62. PubMed ID: 17127360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of the renin-angiotensin system at different sites: effect on renin, angiotensin and aldosterone.
    Abdelrahman AM; Burrell LM; Johnston CI
    J Hypertens Suppl; 1993 Apr; 11(3):S23-6. PubMed ID: 8315514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concerted action of the renin-angiotensin system, mitochondria, and antioxidant defenses in aging.
    de Cavanagh EM; Piotrkowski B; Fraga CG
    Mol Aspects Med; 2004; 25(1-2):27-36. PubMed ID: 15051314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in endothelium-derived hyperpolarizing factor in hypertension and ageing: response to chronic treatment with renin-angiotensin system inhibitors.
    Goto K; Fujii K; Kansui Y; Iida M
    Clin Exp Pharmacol Physiol; 2004 Sep; 31(9):650-5. PubMed ID: 15479174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of protective effects induced by blockade of the renin-angiotensin system: novel role of the pancreatic islet angiotensin-generating system in Type 2 diabetes.
    Leung PS
    Diabet Med; 2007 Feb; 24(2):110-6. PubMed ID: 17257271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of angiotensin II in diabetic nephropathy.
    Kennefick TM; Anderson S
    Semin Nephrol; 1997 Sep; 17(5):441-7. PubMed ID: 9316212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin-angiotensin system inhibitors positively impact on multiple aging regulatory pathways: Could they be used to protect against human aging?
    de Cavanagh EMV; Inserra F; Ferder L
    Physiol Rep; 2024 Jun; 12(12):e16094. PubMed ID: 38924381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined renin-angiotensin system blockade and dietary sodium restriction impairs cardiomyocyte contractility.
    Trongtorsak P; Morgan TO; Delbridge LM
    J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):213-9. PubMed ID: 14689368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-angiotensin blockade improves renal cGMP production via non-AT(2)-receptor mediated mechanisms in hypertension-induced by chronic NOS inhibition in rat.
    Uhlenius N; Vuolteenaho O; Tikkanen I
    J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):233-9. PubMed ID: 11881129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enalapril and losartan attenuate mitochondrial dysfunction in aged rats.
    de Cavanagh EM; Piotrkowski B; Basso N; Stella I; Inserra F; Ferder L; Fraga CG
    FASEB J; 2003 Jun; 17(9):1096-8. PubMed ID: 12709417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogen-activated protein kinase activation.
    Zhang GX; Lu XM; Kimura S; Nishiyama A
    Cardiovasc Res; 2007 Nov; 76(2):204-12. PubMed ID: 17698051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired quality control of mitochondria: aging from a new perspective.
    Weber TA; Reichert AS
    Exp Gerontol; 2010 Aug; 45(7-8):503-11. PubMed ID: 20451598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.